369-25-5Relevant articles and documents
ALK5 INHIBITORS
-
Paragraph 0479; 0738; 0739, (2020/07/07)
The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.
Ruthenium-catalyzed hydrogenation of CO2as a route to methyl esters for use as biofuels or fine chemicals
Li, Yong,Liu, Qingbin,Ma, Yanping,Solan, Gregory A.,Sun, Wen-Hua,Wang, Zheng,Zhang, Qiuyue,Zhao, Ziwei,Zhong, Yanxia
, p. 6766 - 6774 (2020/08/25)
A novel robust diphosphine-ruthenium(ii) complex has been developed that can efficiently catalyze both the hydrogenation of CO2 to methanol and its in situ condensation with carboxylic acids to form methyl esters; a TON of up to 3260 is achievable for the CO2 to methanol step. Both aromatic and aliphatic carboxylic acids can be transformed to their corresponding methyl esters with high conversion and selectivity (17 aliphatic and 18 aromatic examples). On the basis of a series of experiments, a mechanism has been proposed to account for the various steps involved in the catalytic pathway. More importantly, this approach provides a promising route for using CO2 as a C1 source for the production of biofuels, fine chemicals and methanol.
BICYCLIC SULFONES AND SULFOXIDES AND METHODS OF USE THEREOF
-
Paragraph 0439-0440, (2019/05/15)
The invention provides novel compounds having the general formula I: wherein R1, RB1, RB2, n, p, q, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds, and methods of usi
